Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022.
EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help
